Expand BCAX Menu
BCAX MENU

Bicara Therapeutics (BCAX) closed at $9.60 on November 17, 2026, down 1.5% from the previous close, on volume of 852,639 shares (30-day average 1,732,505).

Key numbers
  • Last close: $9.60 (November 17, 2026)
  • 52-week range: $7.87 to $30.99
  • Market value: $637.3 million
  • 30-day implied volatility (IV30): 68.7%
  • Option volume: 1 contracts (0 calls, 1 puts); 30-day average 203

Data as of November 17, 2026.

BCAX Stock Summary and Trading Ideas (Bicara Therapeutics | NASDAQ:BCAX)

Charts for Today's Stock Price and Implied Volatility in Bicara Therapeutics

17-Nov-2026

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for BCAX by Theoretical Edge and Win Rates

Sentiment

Largest Multi-Leg Option Trades (30 Days)

#DateStrategyLegsContracts
1 Oct 20, 2026 Straddle or Synthetic 18-Dec-2620 C : 20 P 600

Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days

Trading Statistics

Key Ratios

Bicara Therapeutics (BCAX) Frequently Asked Questions

What does Bicara Therapeutics do?

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

What symbol and exchange does Bicara Therapeutics shares trade?

Bicara Therapeutics trades on the NASDAQ stock market under the symbol BCAX.

What is Bicara Therapeutics stock price doing today?

As of November 17, 2026, BCAX stock price declined to $9.60 with 852,639 million shares trading.

What is Bicara Therapeutics's Beta?

BCAX has a beta of 1.38, meaning it tends to be more sensitive to market movements. BCAX has a correlation of 0.04 to the broad based SPY ETF.

How much is Bicara Therapeutics worth?

BCAX has a market cap of $637.32 million. This is considered a Small Cap stock.

What are the top ETFs holding Bicara Therapeutics?

The top ETF exchange traded funds that BCAX belongs to (by Net Assets): VTI, IWM, XBI, VXF, VTWO.

Is Bicara Therapeutics (BCAX) a good investment?

BCAX has underperformed the market in the last year with a return of -35.0%, while the SPY ETF gained +10.1%. In the last 3 month period, BCAX fell short of the market, returning -60.5%, while SPY returned -5.4%. However, in the most recent 2 weeks BCAX has outperformed the stock market by returning +21.1%, while SPY returned -2.6%.

What are the support and resistance levels for Bicara Therapeutics (BCAX)?

BCAX support price is $9.21 and resistance is $10.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAX shares will trade within this expected range on the day.

Market Data Delayed 15 Minutes